EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems

Jeremy Kratz, Karen Merritt, Jessica Jorgensen, Comfort Kanji, Luis Abel Quiñones, Daniel L Hertz iD

American Society of Clinical Oncology Educational Book · 2026-06 · 46 (3)

DOI: 10.1200/edbk-26-521184 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2026-06. Verfasst von Jeremy Kratz und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI. Hauptthemen laut MEDLINE: Dihydrouracil Dehydrogenase (NADP), Neoplasms, Antimetabolites, Antineoplastic, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recent regulatory and guideline changes have established pretreatment DPYD genotyping as a critical strategy to prevent severe fluoropyrimidine toxicity. Following earlier European leadership by the European Medicines Agency, the US Food and Drug Administration added boxed warnings to capecitabine and 5-fluorouracil labels recommending genetic testing before therapy. Concurrent updates from the National Comprehensive Cancer Network and ASCO align US with European practice supporting universal testing. Fluoropyrimidines remain foundational treatments across multiple cancers but can cause life-threatening toxicity in patients with dihydropyrimidine dehydrogenase (DPD) deficiency, most commonly because of inherited DPYD variants. DPYD variant carriers receiving standard doses experience markedly increased risk of severe toxicity and treatment-related mortality, emphasizing the clinical importance of DPYD testing and genotype-guided dosing. Evidence demonstrates that dose individualization based on guidance from the Clinical Pharmacogenetics Implementation Consortium reduces toxicity risk while maintaining treatment effectiveness and potentially reducing overall costs. Patient advocacy, particularly efforts led by Advocates for Universal DPD/ DPYD Testing, has accelerated policy change, increased clinician awareness, and highlighted ethical implications of preventable harm. Despite growing adoption, implementation challenges persist, including workflow integration, clinician education, and equitable access. Integrated health systems such as the Veterans Health Administration demonstrate how centralized infrastructure and clinical decision support can facilitate uptake. Barriers are more pronounced in resource-constrained settings, where limited infrastructure, reimbursement uncertainty, and insufficient pharmacogenomic education hinder implementation. Regional initiatives illustrate education-focused, context-adapted strategies to expand testing and address population-specific variant knowledge gaps. Collectively, emerging evidence, regulatory alignment, and advocacy efforts position DPYD genotyping as a patient-safety imperative necessary to achieve safer, more equitable fluoropyrimidine therapy worldwide.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dihydrouracil Dehydrogenase (NADP)NeoplasmsAntimetabolites, AntineoplasticDrug-Related Side Effects and Adverse ReactionsHumansGenetic TestingCapecitabineDelivery of Health CareFluorouracilGenotype

Substanzen

Dihydrouracil Dehydrogenase (NADP)CapecitabineFluorouracilAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI.
  • Center for Human Genomics and Precision Medicine, University of Wisconsin, Madison, WI.
  • William S. Middleton Memorial Veterans Hospital, Madison, WI.
  • Advocates for Universal DPD/DPYD Testing (AUDT), Chelan, WA.
  • University of Wisconsin Hospitals and Clinics, Madison, WI.
  • Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI.

ORCID-Profile: Daniel L Hertz

Zitieren

APA

Kratz, J., Merritt, K., Jorgensen, J., Kanji, C., Quiñones, L. A., & Hertz, D. L. (2026). Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems. American Society of Clinical Oncology Educational Book, 46(3). https://doi.org/10.1200/edbk-26-521184

Vancouver

Kratz J, Merritt K, Jorgensen J, Kanji C, Quiñones LA, Hertz DL. Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems. American Society of Clinical Oncology Educational Book. 2026;46(3). doi:10.1200/edbk-26-521184

BibTeX
@article{Kratz2026,
  author = {Kratz, Jeremy and Merritt, Karen and Jorgensen, Jessica and Kanji, Comfort and Quiñones, Luis Abel and Hertz, Daniel L},
  title = {Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2026},
  volume = {46},
  number = {3},
  doi = {10.1200/edbk-26-521184}
}
Kostenlos starten →